Enzalutamide Induces Cytotoxicity in Desmoplastic Small Round Cell Tumor Independent of the Androgen Receptor.
DSRCT
hormone-sensitive cancer
pediatric cancer
sarcoma
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
06 Nov 2023
06 Nov 2023
Historique:
pubmed:
21
11
2023
medline:
21
11
2023
entrez:
21
11
2023
Statut:
epublish
Résumé
Desmoplastic Small Round Cell Tumor (DSRCT) is a rare, pediatric cancer caused by the EWSR1::WT1 fusion protein. DSRCT predominantly occurs in males, which comprise 80-90% of the patient population. While the reason for this male predominance remains unknown, one hypothesis is that the androgen receptor (AR) plays a critical role in DSRCT and elevated testosterone levels in males help drive tumor growth. Here, we demonstrate that AR is highly expressed in DSRCT relative to other fusion-driven sarcomas and that the AR antagonists enzalutamide and flutamide reduce DSRCT growth. However, despite these findings, which suggest an important role for AR in DSRCT, we show that DSRCT cell lines form xenografts in female mice at the same rate as male mice and AR depletion does not significantly alter DSRCT growth
Identifiants
pubmed: 37986851
doi: 10.1101/2023.11.06.565842
pmc: PMC10659336
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIH HHS
ID : S10 OD024977
Pays : United States
Références
Cancer Res. 2014 Aug 15;74(16):4526-35
pubmed: 24934812
Surg Oncol. 2019 Jun;29:107-112
pubmed: 31196472
Cells. 2020 Dec 10;9(12):
pubmed: 33321757
Sci Rep. 2020 Dec 10;10(1):21750
pubmed: 33303959
Res Rep Urol. 2018 Feb 16;10:23-32
pubmed: 29497605
Nat Methods. 2020 Feb;17(2):137-145
pubmed: 31792435
Cancer Chemother Pharmacol. 2007 Mar;59(4):429-37
pubmed: 16896931
Methods Mol Biol. 2016;1418:283-334
pubmed: 27008021
Cancers (Basel). 2021 Dec 02;13(23):
pubmed: 34885181
Int J Cancer. 2008 Nov 1;123(9):2222-7
pubmed: 18688847
Nature. 2008 Dec 4;456(7222):593-8
pubmed: 19052619
Cancer. 2009 Aug 1;115(15):3526-36
pubmed: 19548262
Cancer Res. 1991 Jul 15;51(14):3814-7
pubmed: 2065335
Cureus. 2021 Mar 18;13(3):e13986
pubmed: 33884237
J Pathol. 2009 Jan;217(1):83-93
pubmed: 18855877
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Genome Biol. 2014;15(12):550
pubmed: 25516281
Semin Cancer Biol. 2005 Jun;15(3):197-205
pubmed: 15826834
Cell Rep. 2013 Dec 26;5(6):1704-13
pubmed: 24332856
Clin Cancer Res. 2018 Oct 1;24(19):4865-4873
pubmed: 29871905
PLoS One. 2018 Dec 26;13(12):e0209648
pubmed: 30586455
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Mol Cell Biol. 2012 Jan;32(2):399-414
pubmed: 22083957
Oncol Lett. 2013 May;5(5):1453-1456
pubmed: 23759995
Lab Invest. 2002 Sep;82(9):1175-82
pubmed: 12218078
BMC Cancer. 2023 May 31;23(1):488
pubmed: 37254069
J Surg Res. 2011 Oct;170(2):e243-51
pubmed: 21529833
Cell Syst. 2019 Apr 24;8(4):281-291.e9
pubmed: 30954476
Bioinformatics. 2015 Jul 15;31(14):2382-3
pubmed: 25765347
Pharmacol Ther. 2013 Dec;140(3):223-38
pubmed: 23859952
J Cancer Res Clin Oncol. 2020 Jul;146(7):1659-1670
pubmed: 32279088
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Oncogenesis. 2020 Apr 28;9(4):41
pubmed: 32345977
NAR Cancer. 2021 Aug 14;3(3):zcab033
pubmed: 34409300
J Cancer Epidemiol. 2014;2014:680126
pubmed: 25431592
Front Cell Dev Biol. 2022 Nov 25;10:1048709
pubmed: 36506091
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Dis Model Mech. 2022 Jan 1;15(1):
pubmed: 34841430
Oncogenesis. 2022 Apr 20;11(1):18
pubmed: 35443736
NPJ Precis Oncol. 2022 Apr 4;6(1):21
pubmed: 35379887
Nat Commun. 2022 Jun 1;13(1):3057
pubmed: 35650195
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Sci Rep. 2020 Jul 23;10(1):12318
pubmed: 32703985
Sci Rep. 2019 Sep 24;9(1):13786
pubmed: 31551480
Clin Cancer Res. 2021 Feb 15;27(4):1184-1194
pubmed: 33229458